AbCellera Biologics Inc. - Laporan Laba Rugi (TTM)

AbCellera Biologics Inc.
US ˙ NasdaqGS ˙ CA00288U1066

Laporan Laba Rugi (TTM)

Laporan Laba Rugi AbCellera Biologics Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 28 233 431 448 444 375 489 507 603 485 181 145 50 38 36 33 33 29 23 33
Change (%) 719.53 84.96 3.81 -0.87 -15.45 30.34 3.74 18.90 -19.53 -62.71 -19.81 -65.29 -24.54 -5.89 -7.64 -0.28 -12.53 -19.83 42.23
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 24 57 85 94 104 61 146 159 184 174 72 161 157 176 162 167 170 167 170 169
Change (%) 134.92 49.96 11.23 10.56 -41.32 139.00 9.05 15.16 -5.07 -58.46 121.71 -2.31 12.00 -7.61 2.74 1.83 -1.50 1.92 -1.00
% of Revenue 84.59 24.25 19.66 21.07 23.49 16.31 29.90 31.43 30.44 35.91 40.00 110.58 311.24 461.95 453.51 504.48 515.15 580.10 737.51 513.31
Gross Operating Profit 4 177 346 353 340 314 343 348 420 311 109 -15 -106 -138 -127 -134 -137 -138 -147 -136
Change (%) 3,928.60 96.16 1.99 -3.91 -7.51 9.17 1.47 20.62 -25.85 -65.08 -114.14 592.95 29.30 -8.08 5.68 2.35 1.16 6.45 -7.79
% of Revenue 15.41 75.75 80.34 78.93 76.51 83.69 70.10 68.57 69.56 64.09 60.00 -10.58 -211.24 -361.95 -353.51 -404.48 -415.15 -480.10 -637.51 -413.31
SG&A 9 16 21 31 40 49 56 61 66 67 69 71 72 75 77 81 85 85 84 82
Change (%) 71.74 31.82 50.62 28.43 21.39 15.66 8.82 7.16 1.50 3.40 2.65 1.35 4.69 2.41 5.15 5.49 0.11 -1.93 -1.60
% of Revenue 32.24 6.76 4.82 6.99 9.05 13.00 11.53 12.10 10.90 13.75 38.13 48.80 142.51 197.71 215.14 244.92 259.09 296.50 362.73 250.94
R&D 46 84
Change (%)
% of Revenue 12.37 46.15
OpEx 35 77 113 136 158 171 218 237 267 261 246 253 251 275 263 302 341 312 314 280
Change (%) 119.29 46.66 20.03 16.55 7.93 27.50 8.99 12.66 -2.56 -5.59 2.90 -0.85 9.69 -4.44 14.95 12.79 -8.63 0.66 -10.87
% of Revenue 123.62 33.08 26.23 30.33 35.66 45.52 44.53 46.78 44.32 53.67 135.86 174.33 497.95 723.82 734.94 914.70 1,034.60 1,080.70 1,356.95 850.29
Operating Income -7 156 318 312 286 204 271 270 336 225 -65 -108 -201 -237 -227 -269 -308 -283 -291 -247
Change (%) -2,421.88 103.89 -1.96 -8.45 -28.41 32.72 -0.48 24.39 -33.03 -128.86 66.23 85.84 18.29 -4.21 18.51 14.40 -8.21 2.75 -15.10
% of Revenue -23.62 66.92 73.77 69.67 64.34 54.48 55.47 53.22 55.68 46.33 -35.86 -74.33 -397.95 -623.82 -634.94 -814.70 -934.60 -980.70 -1,256.95 -750.29
Interest Expense -0 -7 -3 -2 -3 -2 -2 -2
Change (%) 8,205.19 -60.20 -18.44 27.14 -0.00 -0.00
% of Revenue -0.29 -2.92 -0.63 -0.49 -0.63 -0.38 -0.37 -0.31
Net Income 0 119 238 229 211 153 205 200 248 159 -50 -74 -129 -146 -147 -153 -176 -163 -168 -166
Change (%) 43,029.67 100.33 -3.79 -8.15 -27.10 33.46 -2.18 23.96 -36.17 -131.65 47.33 74.73 13.36 0.34 4.36 14.68 -7.36 3.08 -1.31
% of Revenue 0.97 51.00 55.24 51.20 47.44 40.90 41.88 39.49 41.17 32.66 -27.71 -50.91 -256.28 -385.00 -410.48 -463.79 -533.33 -564.83 -726.26 -503.91

Source: Capital IQ

Other Listings
DE:8QQ € 3.54
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista